Related Experiment Video

Updated: Jun 2, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe

Philip C De Witt Hamer1, Shahryar E Mir, David Noske

  • 1Department of Neurosurgery, VU University Medical Center, Amsterdam, The Netherlands. p.dewitthamer@vumc.nl

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|May 13, 2011
PubMed

Insights

WEE1 kinase inhibition halts cancer cell division, particularly in tumors with DNA repair defects. Combining WEE1 inhibitors with chemotherapy or radiation shows promise for cancer treatment.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • WEE1 kinase is crucial for the G₂-cell-cycle checkpoint, enabling DNA repair before cell division.
  • Cancer cells, especially those with deficient G₁-arrest (e.g., glioblastoma), rely heavily on G₂-arrest for survival.
  • WEE1 overexpression is observed in various cancers, including glioblastoma and breast cancer.

Purpose of the Study:

  • To investigate the therapeutic potential of WEE1 inhibition in cancer treatment.
  • To evaluate the efficacy of WEE1 inhibition alone and in combination with conventional therapies.
  • To understand the mechanism by which WEE1 inhibition sensitizes cancer cells to DNA-damaging agents.

Main Methods:

  • Preclinical studies using cancer cell lines and animal models.
  • Utilized siRNA and small molecule inhibitors targeting WEE1.
  • Investigated combinations with radiotherapy and cytostatics.

Main Results:

  • WEE1 inhibition decreased cancer cell viability and tumor burden in preclinical models.
  • Combination therapy (WEE1 inhibition + DNA-damaging agents) enhanced anti-cancer effects.
  • Cancer cells with insufficient G₁-arrest were particularly sensitized to WEE1 inhibition.
  • A WEE1 inhibitor advanced to Phase I clinical trials, with observed toxicities including hematologic events and gastrointestinal issues.

Conclusions:

  • WEE1 inhibition is a promising strategy to induce mitotic catastrophe in cancer cells.
  • Combining WEE1 inhibitors with conventional DNA-damaging therapies is a rational approach.
  • Further clinical evaluation is warranted to assess the safety and efficacy of this combination therapy.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...